1h Free Analyst Time
Global Overactive Bladder Therapeutics Market 2020-2024Speak directly to the analyst to clarify any post sales queries you may have.
The overactive bladder therapeutics market is poised to grow by $ 311.17 mn during 2020-2024 progressing at a CAGR of 2% during the forecast period. The reports on overactive bladder therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing number of drug approvals and strategic alliances. In addition, increasing number of drug approvals is anticipated to boost the growth of the market as well.
The overactive bladder therapeutics market analysis includes product segment and geographic landscapes
The overactive bladder therapeutics market is segmented as below:
By Product
- Anticholinergics
- Beta-3 adrenergic agonists
- Other OAB therapeutics
By Geographic Landscapes
- North America
- Europe
- Asia
- ROW
This study identifies the advent of combination therapy as one of the prime reasons driving the overactive bladder therapeutics market growth during the next few years.
The research presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
The overactive bladder therapeutics market covers the following areas:
- Overactive bladder therapeutics market sizing
- Overactive bladder therapeutics market forecast
- Overactive bladder therapeutics market industry analysis
This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading overactive bladder therapeutics market vendors that include AbbVie Inc., Astellas Pharma Inc., Endo International Plc, Johnson & Johnson, Merck & Co. Inc., Mylan NV, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.. Also, the overactive bladder therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The research presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.
This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Table of Contents
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Product
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global overactive bladder therapeutics market: AbbVie Inc., Astellas Pharma Inc., Endo International Plc, Johnson & Johnson, Merck & Co. Inc., Mylan NV, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advent of combination therapy."
According to the report, one of the major drivers for this market is the increasing number of drug approvals.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Astellas Pharma Inc.
- Endo International Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Mylan NV
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
